Psilocybin

New research shows psilocybin causes anxiety in mice through mechanisms distinct from its psychedelic effects. While ketanserin reduces psilocybin’s psychedelic impact by targeting the 5-HT2A receptor, it does not alleviate the anxiety, suggesting different pathways are involved.

New research suggests psilocybin-assisted therapy can lead to both short-term and long-term negative effects, including emotional and cognitive instability, difficulties in therapist-client relationships, and challenges integrating therapy insights, indicating the need for cautious application and further research into its psychological...

Researchers at the University of Michigan found that psilocybin significantly reduced chronic touch-related pain in rats without affecting heat-related pain. The pain relief outlasted the drug's presence in the body, suggesting a central brain mechanism could be responsible.

Researchers recently explored the potential of psilocybin, a compound from magic mushrooms, to combat diabetes. The findings suggest that psilocybin might protect pancreatic β-cells from damage.

A pivotal study explored how patient expectations affect psilocybin therapy outcomes, discovering no significant impact. Interestingly, suggestible individuals showed enhanced benefits, suggesting a unique interplay between mindset and psychedelic therapy effectiveness.

A new study provides evidence that mushroom extract containing psilocybin may offer superior therapeutic effects for psychiatric disorders compared to synthetic psilocybin, suggesting an "entourage effect" of additional compounds enhancing treatment outcomes.

Psilocybin therapy alters brain activity in patients with alcohol use disorder, according to new research, increasing activity in areas associated with emotional regulation and reducing activity in regions linked to craving.

A groundbreaking study sheds light on psilocybin therapy's success in treating depression, highlighting the crucial roles of mystical experiences and ego dissolution, enhanced by music, in surpassing traditional treatments. The findings were published in the International Journal of Mental Health...

A study revealed psilocybin diminishes the amygdala response to angry faces, potentially impacting emotion processing. This discovery underscores its potential for treating conditions like depression and anxiety, highlighting the profound effects of psychedelics on the brain.

A recent study explores psilocybin's effects on larval zebrafish, revealing it enhances exploratory behavior and buffers stress-induced activity changes, offering insights into psychedelic compounds' potential in mental health treatment.

Can groundbreaking treatments for depression and other psychiatric conditions come from substances once considered purely recreational or even taboo? A recent study by researchers at Johns Hopkins Medicine suggests the answer may be yes.

Low doses of MDMA may reduce challenging effects of LSD and psilocybin, increasing positive experiences like love and self-compassion, according to Scientific Reports. This supports the therapeutic potential of "candy flipping" and "hippy flipping."

A study on rats suggests that microdosing psilocybin could reduce stress-induced anhedonia and compulsive behaviors without causing anxiety or schizophrenia-like symptoms. This research offers insights into psilocybin's potential as a therapy for mental health disorders, though further human studies are...

A recent neuroimaging study shows psilocybin, found in magic mushrooms, significantly alters brain connectivity in alcohol-dependent rats. This mirrors effects seen in humans, offering new avenues for researching the therapeutic impact of psychedelics.

Scientists have discovered that rapid-acting antidepressants like ketamine, psilocybin, and scopolamine can alter negative mood biases in rodent models, a symptom common in depressive disorders. This breakthrough, published in Science Translational Medicine, suggests new approaches to treat Major Depressive Disorder...